PDF(Pubmed)
Abstract：
UNASSIGNED: Hematopoietic neoplasms can cause adrenal infarction. In cases of thrombosis occurring at uncommon sites, it is necessary to consider evaluating for the JAK2V617F mutation, even in the absence of notable abnormalities in blood counts.
UNASSIGNED: Adrenal infarction, a rare ailment, has been sporadically linked to hematopoietic neoplasms. A 46-year-old male encountered left adrenal infarction, which coincided with a progressive rise in platelet counts. Subsequent diagnosis revealed myelodysplastic/myeloproliferative neoplasm-unclassifiable, featuring a JAK2V617F mutation. Simultaneously, the patient manifested multiple arteriovenous thromboses, necessitating treatment with edoxaban, aspirin, and hydroxyurea. Following thrombosis resolution, he was transferred to a transplantation center. This report delves into the thrombogenicity linked to the JAK2V617F mutation, while also examining documented instances of adrenal infarction in myeloid neoplasms. We should consider evaluating for JAK2V617F mutation even in cases of thrombosis at unusual sites, including adrenal infarction, even if there are no considerable abnormalities in blood counts.
UNASSIGNED: Adrenal infarction, a rare ailment, has been sporadically linked to hematopoietic neoplasms. A 46-year-old male encountered left adrenal infarction, which coincided with a progressive rise in platelet counts. Subsequent diagnosis revealed myelodysplastic/myeloproliferative neoplasm-unclassifiable, featuring a JAK2V617F mutation. Simultaneously, the patient manifested multiple arteriovenous thromboses, necessitating treatment with edoxaban, aspirin, and hydroxyurea. Following thrombosis resolution, he was transferred to a transplantation center. This report delves into the thrombogenicity linked to the JAK2V617F mutation, while also examining documented instances of adrenal infarction in myeloid neoplasms. We should consider evaluating for JAK2V617F mutation even in cases of thrombosis at unusual sites, including adrenal infarction, even if there are no considerable abnormalities in blood counts.
摘要：
■造血肿瘤可引起肾上腺梗死。在罕见部位发生血栓形成的情况下，有必要考虑评估JAK2V617F突变，即使没有明显的血细胞计数异常。
■肾上腺梗死，一种罕见的疾病，偶尔与造血肿瘤有关.一名46岁男性遭遇左肾上腺梗死,这与血小板计数的进行性上升同时发生。随后的诊断显示骨髓增生异常/骨髓增殖性肿瘤无法分类，具有JAK2V617F突变。同时,患者表现为多个动静脉血栓形成，需要用edoxaban治疗，阿司匹林,和羟基脲。血栓消退后，他被转移到移植中心。本报告深入研究了与JAK2V617F突变相关的血栓形成，同时还检查了骨髓性肿瘤中肾上腺梗塞的记录实例。我们应该考虑评估JAK2V617F突变，即使在异常部位血栓形成的情况下，包括肾上腺梗塞,即使血细胞计数没有相当的异常。
■肾上腺梗死，一种罕见的疾病，偶尔与造血肿瘤有关.一名46岁男性遭遇左肾上腺梗死,这与血小板计数的进行性上升同时发生。随后的诊断显示骨髓增生异常/骨髓增殖性肿瘤无法分类，具有JAK2V617F突变。同时,患者表现为多个动静脉血栓形成，需要用edoxaban治疗，阿司匹林,和羟基脲。血栓消退后，他被转移到移植中心。本报告深入研究了与JAK2V617F突变相关的血栓形成，同时还检查了骨髓性肿瘤中肾上腺梗塞的记录实例。我们应该考虑评估JAK2V617F突变，即使在异常部位血栓形成的情况下，包括肾上腺梗塞,即使血细胞计数没有相当的异常。
